Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548762 | 0.81 | MEN1 (0.46) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL1548225 | 0.77 | CXCL12 (0.44) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL4715845 | 0.76 | LMNA (0.67) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL132328 | 0.76 | SPHK2 (0.59) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL133608 | 0.74 | SPHK2 (0.58) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL1548620 | 0.74 | SPHK2 (0.42) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL1548638 | 0.74 | SPHK2 (0.42) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL1548365 | 0.73 | SPHK2 (0.57) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL1548951 | 0.73 | CYP1B1 (0.39) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL1548764 | 0.73 | SPHK2 (0.51) | MEN1KMT2ALMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557800-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2013-10-15 | — | — | US | claimed |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-21 | — | — | US | claimed |
| US-RE49811-E1 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2024-01-23 | — | — | US | disclosed |
| EP-4134076-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | Redhill Biopharma Ltd. (IL) | 2023-02-15 | — | — | EP | disclosed |
| US-20220160692-A1 | USE OF SK2 INHIBITORS IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY FOR THE TREATMENT OF CANCER | CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (FR) | 2022-05-26 | — | — | US | disclosed |
| US-11090325-B2 | Compositions for treating ebola virus infection | REDHILL BIOPHARMA LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | disclosed |
| US-20210040215-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | Université Toulouse III - Paul Sabatier (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10822415-B2 | Methods for enhancing the potency of the immune checkpoint inhibitors | INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE) (FR) | 2020-11-03 | — | — | US | disclosed |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | REDHILL BIOPHARMA LTD (IL) | 2020-05-21 | — | — | US | disclosed |
| US-20200113881-A1 | METHOD FOR TREATING CANCER WITH COMBINATION THERAPY | REDHILL BIOPHARMA LTD (IL) | 2020-04-16 | — | — | US | disclosed |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| US-20160113954-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | REDHILL BIOPHARMA LTD. (IL) | 2016-04-28 | — | — | US | disclosed |
| EP-1904439-B1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTHECHNOLOGY CORP (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8557800-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-8063248-B2 | 3-(4-Chloro-phenyl)-adamantane-1-carboxylic acidisopropylamide; antiproliferative, antiinflammatory agent, angiogenesis inhibitor; sphingolipid-derived signaling pathway; coupling acid or acylhalide of phenyl-adamantane derivatives with aminoalkyl-pyridine | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113954-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | RNMT, EIF2AK2, POLRMT | MEN1 4547/4885KMT2A 2632/4885LMNA 1570/4885 |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, S1PR1 | MEN1 2111/4885KMT2A 3321/4885LMNA 1777/4885 |
| US-20220160692-A1 | USE OF SK2 INHIBITORS IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY FOR THE TREATMENT OF CANCER | SPHK2, SPHK1, S1PR2 | MEN1 1730/4885KMT2A 656/4885LMNA 3598/4885 |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | NEFM, EIF2AK2, IRF3 | MEN1 2439/4885KMT2A 4481/4885LMNA 894/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | MEN1 4490/4885KMT2A 4046/4885LMNA 3037/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | MEN1 2111/4885KMT2A 3321/4885LMNA 1777/4885 |
| US-10946000-B2 | Method for treating cancer with combination therapy | TPMT, KRAS, SDHA | MEN1 3237/4885KMT2A 245/4885LMNA 3895/4885 |
| US-20210040215-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | CD274, PDCD1, PDCD1LG2 | MEN1 304/4885KMT2A 317/4885LMNA 3972/4885 |
| US-10822415-B2 | Methods for enhancing the potency of the immune checkpoint inhibitors | CD274, PDCD1, PDCD1LG2 | MEN1 304/4885KMT2A 317/4885LMNA 3972/4885 |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | KRAS, ACE, TPMT | MEN1 2303/4885KMT2A 425/4885LMNA 4075/4885 |
| US-20200113881-A1 | METHOD FOR TREATING CANCER WITH COMBINATION THERAPY | TPMT, KRAS, SDHA | MEN1 3237/4885KMT2A 245/4885LMNA 3895/4885 |
| US-11090325-B2 | Compositions for treating ebola virus infection | NEFM, EIF2AK2, IRF3 | MEN1 2439/4885KMT2A 4481/4885LMNA 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.